STOCKHOLM, May 16, 2018 — BioLamina and collaborators have partnered with Novo Nordisk A/S (Novo Nordisk), a Danish multinational pharmaceutical company, allowing Novo Nordisk to develop novel stem cell based therapies based on Biolaminins, human recombinant laminin cell culture matrices, developed and produced by BioLamina. [Read more…]
Market Players Developing iPS Cell Therapies
While a number of companies have dabbled in this space, the following players are leaders in the development of iPS cell therapies: Cellular Dynamics International (a Fujifilm Company), Cynata Therapeutics, RIKEN, and Astellas (previously Ocata Therapeutics).
iPS Cell Therapy Market Players
In this article:
- Cellular Dynamics International, Owned by FujiFilm
- Cynata Therapeutics
- RIKEN
- Astellas, Previously Ocata Therapeutics
Leading iPS Cell Therapy Companies
The four companies and organizations below are major innovators of iPSC therapeutics.
[Read more…]
Nohla Therapeutics Secures $45 Million to Develop Cord Blood Treatment for Leukemia
Nohla Therapeutics Announces Closing of $45 Million Series B Financing
Proceeds to Support the Development of Dilanubicel (NLA101)Â and Additional Platform Programs
Seattle, WA; May 15, 2018 – Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases, today announced the closing of a $45 million Series B financing. In this round, Fidelity Management and Research Company and Celgene Corporation (Nasdaq: CELG) joined existing investors, ARCH Venture Partners, 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners, who also participated in the financing. [Read more…]
Geographical Differences in Cord Blood Banking
This article explores geographical differences in cord blood banking within key regions of the world. While market factors can vary by geography, it is crucial to have a global understanding of the market. Research advances, clinical trial findings, and technology advances do not know international boundaries.
The cord blood market is global in nature and understanding dynamics limited to your region is not sufficient for making strategic, informed, and profitable decisions.
In this article:
ExCellThera Developing Cord Blood Expansion Technology ECT-001 for Multiple Myeloma
ECT-001 is basis of new clinical trial for multiple myeloma
MONTREAL, May 14, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced today that its lead platform, ECT-001, will be used as part of a new Phase I/II clinical trial in patients with multiple myeloma. The study will enroll up to 20 high-risk, multiple myeloma patients from the Hôpital Maisonneuve-Rosemont in Montreal, Canada. [Read more…]
- « Previous Page
- 1
- …
- 235
- 236
- 237
- 238
- 239
- …
- 336
- Next Page »